Previous epidemiologic studies have suggested an association between maternal sex hormone use during pregnancy, including infertility medication, and an increased risk of neuroblastoma in the offspring. The authors conducted a case-control interview study from 1992 to 1996 that included 504 children less than 19 years of age whose newly diagnosed neuroblastoma was identified by two national collaborative clinical trials groups in the United States and Canada, the Children's Cancer Group and the Pediatric Oncology Group. Controls, matched to cases on age, were identified by random digit dialing. No association was found for use of oral contraceptives before or during pregnancy (first trimester odds ratio (OR) = 1.0, 95% confidence interval (Cl): 0.5, 2.1). The odds ratio was slightly elevated for history of infertility (OR = 1.4, 95% Cl: 0.9, 2.1) and ever use of any infertility medication (OR = 1.2, 95% Cl: 0.7, 2.2). Specifically, ever use of clomiphene was associated with a 1.6-fold increased risk (95% Cl: 0.8, 3.0) but not periconceptionally or during the index pregnancy. A suggestive pattern was found for gender of the offspring, with an increased risk for males but not for females after exposure to oral contraceptives or clomiphene. This study did not find consistent and large increased risks for maternal use of hormones, but the suggestion of an association for male offspring requires further consideration. Am J Epidemiol 1999:150:930-8. child; fertility agents; hormones; neuroblastoma; pregnancy; sex Neuroblastoma is an embryonal tumor derived from neural crest cells that involve the sympathetic ganglia, adrenal medulla, and other sites (1). It is the most common tumor in infants and the second most common solid tumor of childhood. This relatively early age at diagnosis suggests a possible etiologic relation with preconception and in utero exposures. In addition, neuroblastoma has several biologic features, such as
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child; fertility agents; hormones; neuroblastoma; pregnancy; sex Neuroblastoma is an embryonal tumor derived from neural crest cells that involve the sympathetic ganglia, adrenal medulla, and other sites (1) . It is the most common tumor in infants and the second most common solid tumor of childhood. This relatively early age at diagnosis suggests a possible etiologic relation with preconception and in utero exposures. In addition, neuroblastoma has several biologic features, such as MYCN oncogene amplification, that may provide useful markers for the identification of etiologically distinct subgroups (1) .
Several epidemiologic studies have reported associations with a variety of environmental and other exposures (2-6). Of these risk factors, some but not all studies have found an increased risk of neuroblastoma associated with maternal use of sex hormones before and during pregnancy (4) (5) (6) . One recent study reported a 10-fold increase in risk for hormone use related to infertility (6) . The risk was particularly elevated among exposed male children. Use of these medications is possible during early gestation prior to the recognition and diagnosis of pregnancy by the woman and her physician. The possibility that in utero exposure to sex hormones may be associated with carcinogenic effects in human offspring has been suggested and most notably demonstrated in studies of diethylstilbestrol (7, 8) .
We evaluated maternal medication use as part of a large case-control study of risk factors for neuroblastoma. This report focuses on sex hormone use, infertility, and medication use related to infertility.
MATERIALS AND METHODS
Cases were those patients less than 19 years of age who were newly diagnosed with neuroblastoma at one of 139 participating hospitals in the United States and Canada in 1992-1996. The hospitals are members of either of two pediatric collaborative clinical trials groups, the Children's Cancer Group and the Pediatric Oncology Group (9, 10) . (Participating principal investigators and institutions, and their corresponding grant numbers, are listed in appendix tables 1 and 2.) The treating physician provided consent to approach the parents for permission to participate in the study. Case eligibility criteria included availability of the biologic mother, ability of that mother to speak either English or Spanish, and the existence of a telephone in the home. A total of 741 potentially eligible cases were identified, and 538 of the mothers were interviewed successfully (73 percent of those eligible). Reasons for nonparticipation included physician refusal (n = 90, 12 percent), refusal (n = 57, 8 percent), not traceable (n = 44, 6 percent), and other reasons (n = 12, 2 percent).
One control for each case was identified by using a random digit dialing procedure (11) . The procedure is based on adding two random digits to the first eight digits of the home telephone number of the case. Each randomly generated telephone number of a control was tried six times or until a final disposition was reached. Numbers were called twice during the day on weekdays, twice during the evening, and twice on the weekend. Each call was made on different days and at different hours of the day. Controls were individually matched to cases on date of birth (±6 months for cases <3 years of age and ±1 year for cases >3 years of age). Eligibility criteria for controls were the same as those for cases. The response proportion was 74 percent for the screening phase of the random digit dialing procedure. Of the 703 eligible mothers of controls who were identified, 142 (20 percent) refused to participate and 57 (8 percent) could not be located. An interview was completed for 504 mothers of controls (72 percent of those eligible). The analysis was based on the 504 available matched case-control pairs.
The mothers of the cases and controls were contacted after a signed consent form was received. After initial contact, the parents were sent a packet with consent forms and an interview guide. The interview guide contained lists of exposures, including medications, and was used to facilitate recall and increase interview efficiency. A structured telephone interview was then conducted with the mother, and information was collected on demographic factors, pregnancy history, birth defects in offspring, pregnancy and birth complications, radiation exposure, occupational history, family medical history, and tobacco use and alcohol consumption.
Information on hormone and fertility medication use was gathered in two separate sections of the questionnaire. One included specific questions on contraceptive use, such as ever use of birth control pills, pill name, whether exposure occurred when the mother was pregnant, and use of other types of birth control. Specific questions were asked about visiting a physician because of difficulty in becoming pregnant, treatment received, use of fertility drugs such as clomiphene, and dates of use. In addition, we inquired about pregnancy complications, such as vaginal bleeding and threatened miscarriage, that might be indications for hormone use.
The main questionnaire section prompted maternal recall of past medication use by first asking mothers if they had ever used a medication for a specific indication, such as oral contraception or treatment of infertility. Positive responses to these prompts were followed by questions on the specific name of the medication, time period of use (2-12 months before pregnancy, in the month before pregnancy, and by trimester), and frequency and duration of use. Medications were coded by using the Slone Epidemiology Unit, Boston University School of Medicine (Brookline, Massachusetts) drug dictionary coding system. The analysis was based on groups of medications used for the same indication (oral contraceptives and fertility drugs) and, where possible, on specific medications. Specific fertility drugs included clomiphene, medroxyprogesterone acetate, menotropins, urofollitropin, danazol, leuprolide acetate, bromocriptine, and human chorionic gonadotropin. Reported fertility drugs that act by inducing ovulation (clomiphene, bromocriptine, menotropins) were evaluated as a separate group. The medication variables were analyzed within four distinct time windows defined by ever use, use 2-12 months prior to pregnancy, use 1 month before pregnancy, and use during the first trimester. The last menstrual period, as estimated by maternal recall, was used to define the start date of the index pregnancy.
Conditional logistic regression analysis was used to estimate the odds ratios and 95 percent confidence intervals for matched data (12) . Factors evaluated as potential confounders included child's gender; parents' age, tobacco use, and alcohol consumption; and mother's race, education, report of household income in the subject's birth year, parity, gravidity, history of miscarriage, history of induced abortion, and multivitamin use. Given the results of previous studies, we also examined potential effect measure modification by age at diagnosis, gender, and history of miscarriage. Additional exploratory analyses were conducted to evaluate the association with medication use among case subgroups defined by stage of disease and tumor MYCN oncogene amplification status. The international stage classification system (1) was used to classify cases according to stage of disease. Both stage and MYCN oncogene status are strong prognostic factors for neuroblastoma, and use of MYCN oncogene amplification is thought to identify a genetically and clinically distinct subgroup of neuroblastomas (13) . MYCN oncogene copy number was determined by either Southern blot analysis (14) or fluorescence in situ hybridization (15) . For this analysis, MYCN oncogene data were available for 381 (76 percent) cases.
RESULTS
The distribution of selected maternal demographic characteristics as well as the index child's gender and age are presented in table 1. Mothers of cases tended to have less education and to report a lower household income in the birth year than mothers of controls.
There were slightly fewer female cases than controls, and the ages of the cases and controls were very similar, as expected by the matching process.
The results of the analysis of oral contraceptive use within each of the four time windows of interest are shown in table 2. Odds ratios adjusted for mother's race, education, and reported household income in the birth year are presented. Further adjustment by maternal age, parity, gravidity, history of induced abortion and miscarriage, and multivitamin use did not alter the odds ratio estimates. The estimates for ever use of oral contraceptives, use 2-12 months prior to pregnancy, use 1 month before pregnancy, or use in the first trimester were all 1.0.
A total of 79 (15.7 percent) mothers of cases and 60 (11.9 percent) mothers of controls reported having There was a suggestion of an increased risk for male compared with female offspring associated with maternal use of oral contraceptives and fertility drugs. The strongest associations were found for male children whose mothers took oral contraceptives 1 month prior to pregnancy (OR = 1. We also explored the risk associated with specific medical conditions that are indications for use of sex hormones during pregnancy, including threatened miscarriage and vaginal bleeding. There was no association with vaginal bleeding (adjusted OR = 1.1, 95 percent CI: 0.8, 1.6). However, an elevated odds ratio was found for threatened miscarriage (OR -1.6, 95 percent CI: 1.0, 2.6). Examination of specific medications used by mothers who reported "threatened miscarriage" showed only one occurrence of hormone use.
DISCUSSION
In general, our results did not indicate a clear and consistent pattern of association between use of sex hormones, particularly oral contraceptives and infertility medications, and an increased risk of neuroblastoma. Ever use of clomiphene prior to the index pregnancy was associated with a moderately increased risk, although chance could explain the finding, as the risks in the year or months prior to pregnancy were reduced. A suggestive pattern of effect modification by gender, specifically elevated risks for male offspring compared with no increase for female offspring, was found for oral contraceptive use and infertility drug use. However, these estimates were generally imprecise because of small numbers of subjects. In addition, there was some inconsistency in the magnitude of the associations depending on the time period relative to pregnancy. Some of the strongest associations were for ever use and use of the hormone in the year prior to pregnancy, time periods apparently not critical to induction of tumors in the conceptus.
Previous epidemiologic studies have suggested an increased risk for neuroblastoma when hormones are taken prior to or during pregnancy. However, results have been inconsistent, and the specific indications for hormone use, the types of hormones used, and the strength of the association have varied among studies. Kramer et al. (4) reported associations for sex hormones used 3 months prior to or during pregnancy, and during pregnancy. Three women (two cases and one control) reported use of fertility drugs. Schwartzbaum
Am J Epidemiol Vol. 150, No. 9, 1999 (5) did not find an association with sex hormone use during the period from 1 year prior to and including birth, but associations were noted for sex hormone use among women with a history of a previous miscarriage or stillbirth and among children diagnosed at less than or equal to 1 year of age.
A series of 24 neuroblastoma cases from Israel also suggested an association with hormone use during pregnancy (16) . The pregnancies of four of the mothers involved hormone exposure; three of the four cases were male. In addition, there have been other reports of cases of neuroblastoma in children conceived through ovulation induction (17, 18) .
A recent case-control study conducted in New York State found several strong associations between maternal hormone use during pregnancy and an increased risk of neuroblastoma in offspring (6) . Use of any hormone during pregnancy was associated with a threefold increase in risk. Elevated but imprecise odds ratios were found for specific indications, including vaginal bleeding and a previous miscarriage. Hormone use for infertility showed a 10-fold increased risk (95 percent CI: 1.2, 90.0); such use was strongly associated among male offspring (OR = 8.4, 95 percent CI: 0.9, 76.5). As noted by the authors, the study did not collect specific data on oral contraceptive use.
Several limitations of previous studies may explain some of the inconsistent results. These studies were relatively small (4-6), one used cancer controls (5), and not all reported results stratified by age at diagnosis (4) or gender (4, 5) . In addition, not all collected information on medication use for specific types of hormones and oral contraceptives (5, 6) .
Our study had a number of strengths, including a large sample size, detailed questionnaire items on medication use, and extensive covariate data. Nonetheless, it was limited by a response rate of less than 80 percent among mothers of cases and controls. We do not have any data to characterize nonrespondents and evaluate potential selection bias. Because potential differences in the response proportions among mothers of cases and controls can result in socioeconomic-related differences, we attempted to account for this by adjusting for income and education.
Another concern affecting all of the case-control studies is maternal recall. Few studies of birth defects or childhood cancer have directly assessed the accuracy of maternal recall of medication use, complications, and other factors before, during, and after pregnancy. By using interview and obstetric records from mothers of children with birth defects and of healthy controls, Werler et al. (19) found more accurate reporting among mothers of cases of history of untreated or treated infertility and of use of birth control (other than the rhythm method) after conception. Concerns have been raised about this report, including the use of obstetric records as a "gold standard," the high proportion of nonresponse, and the imprecision of these ratio estimates (20) . Werler et al. (21) did note that among clinic patients who as a group had a 100 percent response rate, the relative sensitivity for oral contraceptive use was still higher for cases but similar with respect to infertility history. The study results raise concern regarding potential recall bias for some study exposures. However, further investigation of potential recall bias in studies of birth defects and childhood cancer is needed.
The Michalek et al. (6) study and, to a lesser extent, this study found elevated risk estimates for male offspring. Caution is necessary when interpreting our findings for male children because of the weak to moderate magnitude of the associations, the timing of exposure, and the possible role of chance. The biologic explanation for this finding is unclear, although the issue of potential sensitivity of male offspring to hormones and other exogenous exposures has been raised in relation to genital anomalies and cancer (22, 23) . However, specific experimental data related to hormone exposure of male embryos and fetuses and the development of neuroblastoma or related tumors are lacking and may warrant further investigation in epidemiologic and animal studies.
